Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
CXCR4
HSNCC
PET
PET/CT
[68Ga]Ga-PentixaFor
head and neck squamous cell carcinoma
Journal
American journal of nuclear medicine and molecular imaging
ISSN: 2160-8407
Titre abrégé: Am J Nucl Med Mol Imaging
Pays: United States
ID NLM: 101564121
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
08
2023
accepted:
10
09
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
The aim of this study was to determine the read-out capabilities of the novel C-X-C motif chemokine receptor 4 (CXCR4)-targeting radiotracer [ 12 patients with histologically confirmed HNSCC were scheduled for [ On visual assessment, [ In HNSCC, [
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to determine the read-out capabilities of the novel C-X-C motif chemokine receptor 4 (CXCR4)-targeting radiotracer [
MATERIAL AND METHODS
METHODS
12 patients with histologically confirmed HNSCC were scheduled for [
RESULTS
RESULTS
On visual assessment, [
CONCLUSIONS
CONCLUSIONS
In HNSCC, [
Types de publication
Journal Article
Langues
eng
Pagination
208-216Informations de copyright
AJNMMI Copyright © 2023.
Déclaration de conflit d'intérêts
R.A.W. has received speaker honoraria from PentixaPharm and is involved in [68Ga]Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN), sponsored and planned by PentixaPharm.
Références
AJR Am J Roentgenol. 2017 Aug;209(2):289-303
pubmed: 28731808
Laryngorhinootologie. 2000 Apr;79(4):201-6
pubmed: 10838683
Cancer. 2004 Dec 1;101(11):2641-9
pubmed: 15517576
N Engl J Med. 2016 Apr 14;374(15):1444-54
pubmed: 27007578
J Neurol Surg B Skull Base. 2019 Feb;80(1):18-22
pubmed: 30733896
Radiother Oncol. 2021 Feb;155:204-211
pubmed: 33252044
Nat Immunol. 2004 Sep;5(9):943-52
pubmed: 15300245
J Nucl Med. 2023 Jul;64(7):1009-1016
pubmed: 37290799
Theranostics. 2017 Apr 8;7(6):1589-1597
pubmed: 28529638
JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1037-1043
pubmed: 30242338
Adv Exp Med Biol. 2014;816:107-27
pubmed: 24818721
Eur J Cancer. 2017 Nov;85:6-14
pubmed: 28881249
Clin Nucl Med. 2023 Jan 1;48(1):35-42
pubmed: 36354691
Ann Nucl Med. 2013 Dec;27(10):880-5
pubmed: 23979967
Endocrine. 2022 Oct;78(1):169-176
pubmed: 35751778
J Nucl Med. 2023 Jan;64(1):34-39
pubmed: 35738903
Head Neck. 2019 Apr;41(4):1007-1015
pubmed: 30676682
Strahlenther Onkol. 2013 Mar;189(3):197-201
pubmed: 23329277
Head Neck. 2017 Sep;39(9):1733-1743
pubmed: 28650113
Annu Rev Immunol. 2022 Apr 26;40:413-442
pubmed: 35113731
Cancer Res. 1986 Aug;46(8 Suppl):4244s-4248s
pubmed: 3524805
J Nucl Med. 2022 Jun;63(6):875-881
pubmed: 34593594
Semin Nucl Med. 2021 Nov;51(6):633-645
pubmed: 34246448
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
JAMA Netw Open. 2021 Apr 1;4(4):e217083
pubmed: 33881529
J Nucl Med. 2022 Nov;63(11):1687-1692
pubmed: 35241482
Radiother Oncol. 2018 Jan;126(1):125-131
pubmed: 29061496
J Nucl Med. 2022 May;63(5):727-734
pubmed: 34385340
Oncotarget. 2017 Nov 20;8(68):112739-112747
pubmed: 29348861